CERTOLIZUMAB TROUGH LEVELS AND ANTIBODIES IN INFLAMMATORY BOWEL DISEASE: A SINGLE-CENTER EXPERIENCE

被引：0
|
作者：
Ramos, Guilherme Piovezani
Al-Bawardy, Badr
Willrich, Maria Alice V.
Papadakis, Konstantinos A.
Kane, Sunanda V.
Raffals, Laura H.
Faubion, William
Tremaine, William J.
Loftus, Edward V.
机构：
来源：
GASTROENTEROLOGY | 2018年 / 154卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1855
引用
收藏
页码：S826 / S827
页数：2
相关论文
共 50 条
  • [21] Characteristics and Trends in the Incidence of Inflammatory Bowel Disease in Korean Children: A Single-Center Experience
    Kim, Bong Jin
    Song, Seung Min
    Kim, Kyung Mo
    Lee, Yeoun Joo
    Rhee, Kang Won
    Jang, Joo Young
    Park, Seong Jong
    Yoon, Chong Hyun
    DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (07) : 1989 - 1995
  • [22] Characteristics and outcomes of rectal cancer in patients with inflammatory bowel disease: a single-center experience
    Sameh Hany Emile
    Nir Horesh
    Zoe Garoufalia
    Peter Rogers
    Rachel Gefen
    Giovanna Dasilva
    Steven D. Wexner
    Updates in Surgery, 2024, 76 (1) : 119 - 126
  • [23] Vedolizumab Trough Levels in Inflammatory Bowel Disease: Initial Clinical Experience
    Badr, Al-Bawardy
    Guilherme, Piovezani Ramos
    Loftus, Edward, Jr.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S26 - S26
  • [24] A Single-Center Experience with Dupilumab for Atopic or Psoriasiform Dermatitis in Patients with Inflammatory Bowel Disease
    Elizabeth A. Spencer
    Michael T. Dolinger
    Marla C. Dubinsky
    Digestive Diseases and Sciences, 2023, 68 : 1121 - 1124
  • [25] AGGRESSIVE INFLAMMATORY BOWEL DISEASE PHENOTYPE IN PATIENTS WITH ANKYLOSING SPONDYLITIS: A SINGLE-CENTER EXPERIENCE
    Rumman, Amir
    Al Malki, Fahd
    Al Ghamdi, Sarah
    Tabatabavakili, Sahar
    Cino, Maria
    Inman, Robert
    GASTROENTEROLOGY, 2018, 154 (06) : S624 - S624
  • [26] Adalimumab trough serum levels and clinical response in a single-center cohort of inflammatory bowel disease patients: Can trough serum levels serve as a predictor for future loss of response?
    Karmiris, Konstantinos
    Paintaud, Gilles
    Degenne, Danielle
    Ferrante, Marc
    Duveau, Anne-Claire
    Noman, Maja
    Van Assche, Gert A.
    Vermeire, Severine
    Rutgeerts, Paul
    GASTROENTEROLOGY, 2008, 134 (04) : A68 - A68
  • [27] ANTIBODIES TO INFLIXIMAB AND INFLIXIMAB TROUGH LEVELS IN THE MANAGEMENT OF CHILDREN WITH INFLAMMATORY BOWEL DISEASE
    Dilillo, A.
    Isoldi, S.
    Mallardo, S.
    Civitelli, F.
    Oliva, S.
    Aloi, M.
    Rossi, P.
    Carbogno, S.
    Viola, F.
    Cucchiara, S.
    DIGESTIVE AND LIVER DISEASE, 2016, 48 : E271 - E271
  • [28] Misdiagnosis of Inflammatory Bowel Disease: A Single-Center Case Series
    Zackria, Rasiq
    Pattison, Robert
    Ghobrial, Youssef
    Hsu, Mark
    Stone, Christian Diaz
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S785 - S785
  • [29] Health-related quality of life in patients with inflammatory bowel disease: a single-center experience
    Kalafateli, Maria
    Triantos, Christos
    Theocharis, Georgios
    Giannakopoulou, Dimitra
    Koutroumpakis, Efstratios
    Chronis, Aristidis
    Sapountzis, Apostolos
    Margaritis, Vasileios
    Thomopoulos, Konstantinos
    Nikolopoulou, Vasiliki
    ANNALS OF GASTROENTEROLOGY, 2013, 26 (03): : 243 - 248
  • [30] Infliximab Re-treatment in Inflammatory Bowel Disease: A Single-Center Routine Clinical Experience
    Hughes, Julia T.
    Herfarth, Hans H.
    Isaacs, Kim L.
    Plevy, Scott E.
    Sartor, R. Balfour
    Sheikh, Shehzad Z.
    Hansen, Jonathan J.
    Long, Millie D.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (09) : 1704 - 1705
12345